In this proposal we describe projects that aim to determine the mechanism by which mutations in the tau gene cause the neurodegeneration associated with Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17). In addition we aim to examine the role of Tau in neurodegeneration in other diseases including Progressive supranuclear Palsy (PSP), Alzheimer's Disease, Pick's Disease and Cortico-basal degeneration (CBD). The PI's team reported the identification of missence and splice site mutations in tau, associated with FTDP-17 in the journal """"""""Nature"""""""" in June of this year. The Projects are as follows: The Genetics of FTD and Tauopathies. This project will use genetic analysis to examine the possible association of variation in the tau gene with PSP, Pick's disease and CBD. In addition this project aims to identify the gene on chromosome 3 that is also linked with FTD. Mutations at this locus generate a phenotype that is almost indistinguishable from FTD-17 and thus it is important to identify this gene and determine its relationship, if any, with tau. Pathobiology of neurodegenerative disorders linked to mutations in the tau gene. The location of the missence mutations in the tau gene suggests that these likely affect the ability of Tau to bind microtubules. This project will examine this hypothesis using in vitro tubulin binding assays and will also study the effect of the mutations on the polymerization of Tau into fibrils. In addition this project will examine the effect of mutant Tau in transfected cells and will analyze the Tau from the brains of transgenic mice generated in projects 3 and 4. Analysis of the Role of 3 and 4 Repeat Tau in vitro and in vivo. This project will initially utilize in vitro splicing assays to determine the regulation of exon10 alternative splicing that is disrupted by the FTDP-17 splice site mutations. Subsequent studies that will performed in vitro, in transfected cells, and in vivo, in gene targeted mice, will examine the differing roles of 4 repeat and 3 repeat Tau in neuronal function. In addition the gene targeted tau mice will be used to test the hypothesis that the ratio of Tau4 and 3 repeat isoforms influences the toxicity of Abeta in vivo. Transgenic Modeling of Tauopathy. This project will utilize transgenic animals to model the effect of the Tau missence mutations in vivo. The brains of animals expressing wild type and mutant Tau cDNA constructs will be examined will be examined for the neurofibrillary tangles and neurodegeneration that are associated with FTDP-17. In addition animals expressing Human genomic tau constructs will be studied to see the effect of expressing Human Tau isoforms on Abeta sensitivity. These projects will operate around a Neuropathology Core whose broad goal will be to provide detailed morphological characterization of brains from Human patients and animal models that are derived from the research projects.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG017216-02
Application #
6169509
Study Section
Special Emphasis Panel (ZAG1-BJB-4 (M4))
Program Officer
Snyder, D Stephen
Project Start
1999-09-01
Project End
2004-07-31
Budget Start
2000-08-15
Budget End
2001-07-31
Support Year
2
Fiscal Year
2000
Total Cost
$1,207,231
Indirect Cost
Name
Mayo Clinic, Jacksonville
Department
Type
DUNS #
153223151
City
Jacksonville
State
FL
Country
United States
Zip Code
32224
Kidana, Kiwami; Tatebe, Takuya; Ito, Kaori et al. (2018) Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice. EMBO Mol Med 10:
Li, Zeran; Del-Aguila, Jorge L; Dube, Umber et al. (2018) Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. Genome Med 10:43
Sun, Wenyan; Samimi, Hanie; Gamez, Maria et al. (2018) Pathogenic tau-induced piRNA depletion promotes neuronal death through transposable element dysregulation in neurodegenerative tauopathies. Nat Neurosci 21:1038-1048
Sims, Rebecca (see original citation for additional authors) (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49:1373-1384
Carrasquillo, Minerva M; Allen, Mariet; Burgess, Jeremy D et al. (2017) A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression. Alzheimers Dement 13:663-673
Miller, Jeremy A; Guillozet-Bongaarts, Angela; Gibbons, Laura E et al. (2017) Neuropathological and transcriptomic characteristics of the aged brain. Elife 6:
Sanchez-Contreras, Monica; Heckman, Michael G; Tacik, Pawel et al. (2017) Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration. Mov Disord 32:115-123
Carrasquillo, Minerva M; Barber, Imelda; Lincoln, Sarah J et al. (2016) Evaluating pathogenic dementia variants in posterior cortical atrophy. Neurobiol Aging 37:38-44
Allen, Mariet; Carrasquillo, Minerva M; Funk, Cory et al. (2016) Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases. Sci Data 3:160089
Caberlotto, Laura; Marchetti, Luca; Lauria, Mario et al. (2016) Integration of transcriptomic and genomic data suggests candidate mechanisms for APOE4-mediated pathogenic action in Alzheimer's disease. Sci Rep 6:32583

Showing the most recent 10 out of 215 publications